Cargando…

Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy

BACKGROUND: There is a growing body of evidence in animal and cell based models of Parkinson's disease (PD) to suggest that overexpression and / or abnormal accumulation and aggregation of α-synuclein can trigger neuronal death. This important role of α-synuclein in PD pathogenesis is supported...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganguly, Upasana, Chakrabarti, Sankha Shubhra, Kaur, Upinder, Mukherjee, Anwesha, Chakrabarti, Sasanka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120113/
https://www.ncbi.nlm.nih.gov/pubmed/29189163
http://dx.doi.org/10.2174/1570159X15666171129100944
_version_ 1783352208440426496
author Ganguly, Upasana
Chakrabarti, Sankha Shubhra
Kaur, Upinder
Mukherjee, Anwesha
Chakrabarti, Sasanka
author_facet Ganguly, Upasana
Chakrabarti, Sankha Shubhra
Kaur, Upinder
Mukherjee, Anwesha
Chakrabarti, Sasanka
author_sort Ganguly, Upasana
collection PubMed
description BACKGROUND: There is a growing body of evidence in animal and cell based models of Parkinson's disease (PD) to suggest that overexpression and / or abnormal accumulation and aggregation of α-synuclein can trigger neuronal death. This important role of α-synuclein in PD pathogenesis is supported by the fact that duplication, triplication and mutations of α-synuclein gene cause familial forms of PD. METHODS: A review of literature was performed by searching PubMed and Google Scholar for relevant articles highlighting the pathogenic role of α-synuclein and the potential therapeutic implications of targeting various pathways related to this protein. RESULTS: The overexpression and accumulation of α-synuclein within neurons may involve both transcriptional and post-transcriptional mechanisms including a decreased degradation of the protein through proteasomal or autophagic processes. The mechanisms of monomeric α-synuclein aggregating to oligomers and fibrils have been investigated intensively, but it is still not certain which form of this natively unfolded protein is responsible for toxicity. Likewise the proteotoxic pathways induced by α-synuclein leading to neuronal death are not elucidated completely but mitochondrial dysfunction, endoplasmic reticulum (ER) stress and altered ER-golgi transport may play crucial roles in this process. At the molecular level, the ability of α-synuclein to form pores in biomembranes or to interact with specific proteins of the cell organelles and the cytosol could be determining factors in the toxicity of this protein. CONCLUSION: Despite many limitations in our present knowledge of physiological and pathological functions of α-synuclein, it appears that this protein may be a target for the development of neuroprotective drugs against PD. This review has discussed many such potential drugs which prevent the expression, accumulation and aggregation of α-synuclein or its interactions with mitochondria or ER and thereby effectively abolish α-synuclein mediated toxicity in different experimental models.
format Online
Article
Text
id pubmed-6120113
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-61201132019-02-01 Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy Ganguly, Upasana Chakrabarti, Sankha Shubhra Kaur, Upinder Mukherjee, Anwesha Chakrabarti, Sasanka Curr Neuropharmacol Article BACKGROUND: There is a growing body of evidence in animal and cell based models of Parkinson's disease (PD) to suggest that overexpression and / or abnormal accumulation and aggregation of α-synuclein can trigger neuronal death. This important role of α-synuclein in PD pathogenesis is supported by the fact that duplication, triplication and mutations of α-synuclein gene cause familial forms of PD. METHODS: A review of literature was performed by searching PubMed and Google Scholar for relevant articles highlighting the pathogenic role of α-synuclein and the potential therapeutic implications of targeting various pathways related to this protein. RESULTS: The overexpression and accumulation of α-synuclein within neurons may involve both transcriptional and post-transcriptional mechanisms including a decreased degradation of the protein through proteasomal or autophagic processes. The mechanisms of monomeric α-synuclein aggregating to oligomers and fibrils have been investigated intensively, but it is still not certain which form of this natively unfolded protein is responsible for toxicity. Likewise the proteotoxic pathways induced by α-synuclein leading to neuronal death are not elucidated completely but mitochondrial dysfunction, endoplasmic reticulum (ER) stress and altered ER-golgi transport may play crucial roles in this process. At the molecular level, the ability of α-synuclein to form pores in biomembranes or to interact with specific proteins of the cell organelles and the cytosol could be determining factors in the toxicity of this protein. CONCLUSION: Despite many limitations in our present knowledge of physiological and pathological functions of α-synuclein, it appears that this protein may be a target for the development of neuroprotective drugs against PD. This review has discussed many such potential drugs which prevent the expression, accumulation and aggregation of α-synuclein or its interactions with mitochondria or ER and thereby effectively abolish α-synuclein mediated toxicity in different experimental models. Bentham Science Publishers 2018-08 2018-08 /pmc/articles/PMC6120113/ /pubmed/29189163 http://dx.doi.org/10.2174/1570159X15666171129100944 Text en © 2018 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Ganguly, Upasana
Chakrabarti, Sankha Shubhra
Kaur, Upinder
Mukherjee, Anwesha
Chakrabarti, Sasanka
Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
title Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
title_full Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
title_fullStr Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
title_full_unstemmed Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
title_short Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
title_sort alpha-synuclein, proteotoxicity and parkinson's disease: search for neuroprotective therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120113/
https://www.ncbi.nlm.nih.gov/pubmed/29189163
http://dx.doi.org/10.2174/1570159X15666171129100944
work_keys_str_mv AT gangulyupasana alphasynucleinproteotoxicityandparkinsonsdiseasesearchforneuroprotectivetherapy
AT chakrabartisankhashubhra alphasynucleinproteotoxicityandparkinsonsdiseasesearchforneuroprotectivetherapy
AT kaurupinder alphasynucleinproteotoxicityandparkinsonsdiseasesearchforneuroprotectivetherapy
AT mukherjeeanwesha alphasynucleinproteotoxicityandparkinsonsdiseasesearchforneuroprotectivetherapy
AT chakrabartisasanka alphasynucleinproteotoxicityandparkinsonsdiseasesearchforneuroprotectivetherapy